Introduction {#sec1-1}
============

In at least some of immune thrombocytopenia (ITP) patients, thrombocytopenia is worsened by inappropriately low levels of platelet production, unable to compensate for the increased peripheral immune-mediated destruction of platelets. Until recently, management of ITP adult patients with platelet counts \<30×10^9^/L and/or bleeding signs has relied upon the use of drugs or procedures (*i.e*. splenectomy) aimed at decreasing B-cell and T-cell immune-response to autologous platelets and megakariocytes. The availability of thrombopoietin-receptor agonist (TPO-RA) has offered new opportunities for treating adult ITP patients acting on megakariocyte survival and production of platelets.^[@ref1]^

Thrombopoietin-receptor agonist increase thrombopoiesis activating the c-Mpl receptor on bone marrow megakariocytes, thus providing an additional stimulus to increase their survival and platelet production.^[@ref1]^

Response rates up to 90% in long-term follow-up studieshave been reported with both romiplostim and eltrombopag.^[@ref2],[@ref3]^ However, platelet counts usually return to pretreatment levels upon discontinuation of treatment and long-term, if not life-long, administration was envisioned in order to maintain effective thrombopoiesis.

In recent years sporadic patients have been reported as being able to discontinue treatment with either romiplostim or eltrombopag without relapsing off-therapy.^[@ref4]^ Most studies were not designed to assess feasibility of TPORA discontinuation and thus true prevalence of patients able to maintain remission off therapy can not be inferred.

A French observational study confirms that romiplostim can be successfully discontinued:^[@ref11]^ of the 28/54 responding patients, 8 remained in complete remission off therapy at a median follow up of 13,5 months (range 5-27). Data from a recently presented interim analysis of a phase 2 study of platelet response and remission rates in ITP patients receiving romiplostim show that 11 of 38 evaluable patients (29%) were able to maintain remission (*i.e*. 24 weeks of platelet counts ≥50×10^9^/L) off any treatment.^[@ref12]^

We report our experience with the peptibody romiplostim in a small series of patients unresponsive to immunosuppressive therapy who were treated with this TPO-RA for variable lengths of time. Some of these patients were able to discontinue therapy after achieving response, without relapsing at long-term follow-up.

Case Report {#sec1-2}
===========

Between September 2009 and May 2014 a total of 30 patients (11 M; mean age at romiplostim treatment 50.7 yrs, range 18-82) received romiplostim at two collaborating Centers. Patients with shorter follow-up on treatment with romiplostim or on eltrombopag are not included in the present analysis. Patient characteristics at the time of romiplostim administration are summarized in [Table 1](#table001){ref-type="table"}. Patients were defined either as non responders or refractory according to the International Working Party (IWP) proposed standardization of terminology for ITP.^[@ref13]^ All patients are enrolled in a local Italian registry (REL-ITP registry), and informed consent to demographic and clinical data use is given at enrollment. The REL registry has received approval by the human subjects research review board of both participating hospitals.

Overall, 27/30 patients (90%) responded to romiplostim according to IWP criteria.^[@ref13]^ Of the 27 responders: 1 patient (\#4) was lost to follow-up; 1 patient (\#5) discontinued romiplostim due to acute myocardial infarction, at the time of SAE, romiplostim dose was 10 µg/kg/week and platelet counts were 84×10^9^/L; in 5/27 patients (\#6-10) romiplostim was used as bridge to splenectomy; 5/27 patients (\#11-15) lost response at 11, 6, 11, 12 and 11 months respectively; neutralizing anti-romiplostim antibodies could be searched for in 3/5 patients; in three (\#13, 14 and 15) the test yielded a positive result; the remaining two patients could not be tested; in 2/27 patients (\#16 and 17) romiplostim administration is ongoing (56 and 12 months respectively); 13/27 patients (\#18-30) achieved stable, safe platelet counts and were able to stop romiplostim after a mean of 43.3 weeks (range 12-122) on therapy with sustained response maintained at a mean of 28.8 months (range 15-55).

Data on patients who achieved stable response off therapy are summarized in [Table 2](#table002){ref-type="table"}. Strict platelet monitoring was maintained during follow up off therapy. In 7/13 patients a decreased platelet count compared to a previous control was found weeks from discontinuation of weekly romiplostim administration. These patients were re-exposed to a limited number of *one shot* low (1 or 2 mcg/kg) dose of romiplostim and regained a stable response, as shown for four patients in [Figure 1](#fig001){ref-type="fig"}.

No bleeding events occurred during the observational period. Patient \#29 developed lower limb superficial phlebitis while on romiplostim 1 µg/kg on alternate weeks and warfarin was started; platelets were 135×10^9^/L at the time of the event; screening for lupus anticoagulant, anti-phospholipids antibodies, anti-beta2glycoprotein1 was negative. Romiplostim was discontinued a month later because platelet counts remained stable at around 100×109/L. Three patients (\#18,20,28) had received the last rituximab course 4, 6 and 33 weeks before starting romiplostim; one patient (\#19) received a first course of romiplostim as bridge to splenectomy having failed steroids and cyclosporine; a week after surgery he relapsed with severe thrombocytopenia and was re-treated with romiplostim. He received a total of 7 romiplostim doses administered over a 22 week period of time; romiplostim was discontinued at 22 weeks from splenectomy since stable, ≥100×109/L platelet counts were achieved.

Bone marrow biopsies for detection of fibrous changes during romiplostim use were not performed since most of our patients received treatment for less than 18 months.

Discussion {#sec1-3}
==========

Overall, our experience with romiplostim in real life practice is in line with reported findings from controlled studies with 90% of patients (27/30) responding. However, in our experience the percentage of patients able to discontinue romiplostim without relapsing is noteworthy: 48%, if we consider the whole number of romiplostim responders (13 of 27 responders) and 65% if we consider only patients who received long-term treatment (13 of 20 patients) i.e. not considering patients receiving romiplostim as bridge to splenectomy, lost to follow-up, or who discontinued the drug because of SAE.

In 5 chronic ITP patients out of 13 long term responders, romiplostim seemed to be the only treatment responsible for sustained response. Indeed, it has been proposed that TPO-RA therapy may result in improved immune regulation by regulatory T cells (Tregs) possibly restoring immune tolerance.14

Similar immune-modulating effects have also been described for other treatment modalities (e.g. rituximab, high-dose dexamethasone, intravenous immunoglobulin) which result in sustained responses in a fraction of ITP patients.15,16

In the remaining 8 patients, response might have been either spontaneous (2 newly diagnosed and 3 persistent disease patients) or secondary to rituximab (2 patients) or splenectomy (1 patient). Nevertheless, use of romiplostim may be a treatment option for patients with persistently low platelet counts awaiting for platelet recovery, either it be spontaneous or secondary to disease-modifying treatments for which a possible late-response can be anticipated.

No specific patient's features (e.g. age, ITP duration, lines of previous treatment) nor pattern of early response (*e.g*. dose requirements, time to response) seemed to consistently predict for sustained response off therapy. However, it seems that patients achieving safe platelet counts at lower dosages are probably worth a try of therapy tapering and discontinuation. Manufacturer dose adjustment rules allow romiplostim to be discontinued when appropriate and clinical judgment was used to manage patients.

Moreover, it appears that TPO-RA do not cause tachyphylaxis. This has been specifically tested and demonstrated for eltrombopag and it is conceivable also for romiplostim:^[@ref17]^ one of the patients presented by Newland^[@ref5]^ received a single romiplostim dose after 11 weeks off therapy and regained high platelet counts; thereafter, hemostatic platelet counts were maintained without any therapy for 2 years. Similar results were observed in a fraction of our patients. All 7 patients who were reexposed to romiplostim weeks after weekly administration was stopped ([Table 2](#table002){ref-type="table"} and [Figure 1](#fig001){ref-type="fig"}), regained a platelet response. Knowledge that TPO-RA can be safely administered on a *on-demand* basis without loss of effectiveness offers the possibility of re-exposing relapsed patients without the threat of these patients not being able to regain a response. Moreover, need of *on demand* therapy doesn't seem to predict for lost of long-term response to romiplostim. This new finding is probably worth being taken into account in planning prospective studies of feasibility of romiplostim discontinuation.

The finding that at least 3 of 5 patients who abruptly lost response to romiplostim tested positive for neutralizing antibodies suggests that development of these antibodies may be a more frequent event than expected.

Being a retrospective observational study, our results should be interpreted with caution, but still they suggest that in a significant fraction of patients, in *real world* practice, sustained remission without disease recurrence may be obtained after a relatively short-term administration of romiplostim.

Conclusions {#sec1-4}
===========

To date, because of their known mechanism of action, TPO-RA are thought to be effective only while the treatment is ongoing and the proper dose is being administered. However increasing reported evidence exists on the occurrence of sustained responses after TPORA discontinuation. Our observations support the proposal of using romiplostim as *bridge to recovery*, either it be spontaneous (*e.g.* in newly diagnosed or persistent ITP), TPO-RA induced or representing a late-response to previously administered treatments, rather than long-term treatment. This approach would have relevant clinical implications. First of all, concern about TPO-RA long-term sides effects (marrow fibrosis, increased risk of thrombotic events), especially in younger patients, would be greatly reduced. Moreover, treatment costs, which currently also limit their use^[@ref18]^ would be less of an issue. If results on persistent remissions after short-term romiplostim use were to be confirmed in larger patient population, this approach could be used to defer or avoid splenectomy and to spare patients the untoward effects of prolonged immunosuppressive treatments. This would be especially beneficial in newly diagnosed severe ITP failing first line therapy with steroids. Future biological and intervention studies are needed in order to identify predictive factors of long term sustained response, allowing clinicians to tailor the best treatment for each ITP patient.

the abstract was submitted, accepted and presented at 19th Congress of European Hematology Association, Milan, June 2014.

![Platelet count in 4 patients who achieved a sustained response after romiplostim discontinuation and a limited number of *on-demand* re-exposure to the drug.](hr-2015-1-5673-g001){#fig001}

###### 

Main characteristics of enrolled patients.

  Patient (sex, age)   Age at diagnosis   Age at start of first line   N, P, C at romipl start   N. of previous treatment[\*](#t1-tfn2){ref-type="table-fn"}   Time from any treatment to romiplostim[\*\*](#t1-tfn3){ref-type="table-fn"}
  -------------------- ------------------ ---------------------------- ------------------------- ------------------------------------------------------------- -----------------------------------------------------------------------------
  1 (F, 47)            37                 37                           C                         4                                                             120
  2 (F, 71)            69                 69                           C                         4                                                             24
  3 (F, 33)            11                 15                           C                         4                                                             264
  4 (M, 66)            48                 66                           C                         2                                                             5
  5 (M, 56)            34                 34                           C                         4                                                             264
  6 (F, 22)            20                 20                           P                         3                                                             7
  7 (M, 68)            61                 61                           C                         2                                                             89
  8 (F, 58)            57                 57                           C                         2                                                             12
  9 (F, 24)            24                 24                           N                         2                                                             1
  10 (F, 50)           50                 50                           N                         2                                                             3
  11 (M, 59)           42                 42                           C                         4                                                             204
  12 (F, 55)           55                 55                           N                         2                                                             2
  13 (F, 37)           37                 37                           P                         2                                                             2
  14 (F, 38)           38                 28                           P                         2                                                             6
  15 (M, 18)           18                 18                           N                         2                                                             2
  16 (F, 65)           56                 56                           C                         4                                                             108
  17 (M, 28)           28                 28                           P                         2                                                             7
  18 (F, 60)           60                 60                           P                         2                                                             3
  19 (M, 66)           64                 64                           C                         3                                                             24
  20 (F, 69)           69                 69                           N                         3                                                             3
  21 (M, 20)           11                 11                           C                         2                                                             2
  22 (M, 67)           67                 67                           N                         2                                                             3
  23 (M 42)            41                 41                           N                         2                                                             2
  24 (F, 51)           51                 51                           P                         2                                                             6
  25 (F, 55)           47                 47                           C                         3                                                             96
  26 (F, 42)           20                 20                           C                         5                                                             252
  27 (F, 42)           42                 42                           P                         2                                                             5
  28 (M, 60)           57                 57                           C                         4                                                             26
  29 (F, 82)           79                 80                           C                         4                                                             32
  30 (F,72)            72                 72                           P                         4                                                             9

N, newly; P, persistent; C, chronic.

\*Any type of steroid is considered as a single line of therapy. IVIG given as isolated drug is considered as a single line of therapy. IVIG + steroid if given associated, is considered as a single line of therapy. Other possible therapies: Rituximab, Cyclosporin, Azathioprine, Vincristine.

\*\*Time elapsed (months) from any treatment required for ITP and romiplostim.

###### 

Characteristics of patients who achieved a sustained response after romiplostim discontinuation.

  Patient                                 Sex, age at R start   Plt count at R start (xl0^9^/L)   Max dose R (mcg/kg)   Mean dose R (mcg/kg)   Last dose R (mcg/kg) before suspension   Re exposure: n. of *on-demand* R doses   Time interval at re exposure after R stop (weeks)   Plt at time of re-exposure (xl0^9^/L)   Min-max Plt after R definitive stop (xl0^9^/L)   Duration of R treatment (weeks)   Plt at last follow up (xl0^9^//L)   Time (months) of therapy
  --------------------------------------- --------------------- --------------------------------- --------------------- ---------------------- ---------------------------------------- ---------------------------------------- --------------------------------------------------- --------------------------------------- ------------------------------------------------ --------------------------------- ----------------------------------- --------------------------
  18                                      F, 60                 2                                 1                     1                      1                                        0                                        n.a                                                 n.a                                     210-320                                          12                                250                                 55
  19[\*](#t2-tfn2){ref-type="table-fn"}   M, 66                 13                                7                     3,5                    2                                        2                                        4,+7                                                12,25                                   94-324                                           22                                287                                 31
  20                                      F, 69                 4                                 3                     1,5                    1                                        10                                       4 (10 wkly doses)                                   63                                      96-120                                           37                                145                                 19
  21                                      M,20                  1                                 6                     3,3                    5                                        0                                        n.a                                                 n.a                                     194-334                                          15                                243                                 43
  22                                      M, 67                 11                                5                     3,09                   2                                        2                                        4,+11                                               67,64                                   67-314                                           25                                118                                 35
  23                                      M,42                  1                                 7                     3,3                    3                                        0                                        n.a                                                 n.a                                     207-355                                          14                                134                                 15
  24                                      F, 51                 22                                7                     3,3                    1                                        3                                        3, +4, +4                                           35,60,37                                84-153                                           68                                128                                 20
  25                                      F,55                  20                                6                     3,8                    6                                        0                                        n.a                                                 n.a                                     67-298                                           122                               115                                 19
  26[\*](#t2-tfn2){ref-type="table-fn"}   F, 42                 22                                5                     2,7                    2                                        0                                        n.a                                                 n.a                                     243-411                                          16                                210                                 19
  27                                      F,42                  21                                2                     1,8                    1                                        2                                        3,+ 3                                               38,40                                   52-120                                           62                                87                                  15
  28[\*](#t2-tfn2){ref-type="table-fn"}   M,60                  5                                 3                     1,71                   1                                        4                                        12,+7,+4,+7                                         31,42,76,91                             155-313                                          63                                113                                 44
  29[\*](#t2-tfn2){ref-type="table-fn"}   F, 82                 21                                1                     0,5                    1                                        1                                        10                                                  75                                      63-289                                           94                                107                                 32
  30[\*](#t2-tfn2){ref-type="table-fn"}   F, 72                 10                                3                     2,09                   2                                        0                                        n.a                                                 n.a                                     138-281                                          27                                121                                 28
  Mean (range)                            56                    11.7                              4.3                   2.43                   2.1                                      --                                       --                                                  --                                      min 128                                                                            158.3                               28.8
                                          (42-82)               (1-22)                            (1-7)                 (0.5-3.8)              (1-6)                                                                                                                                                                         (52-243)                                         44.3 (12-122)                     (87-287)                            (15-55)

R, Romiplostim; Pit, platelet; n.a, not applicable. Mean dose of Romiplostim: it is calculated as the mean of all administered doses during all period of treatment.

\*Splenectomized patients.
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